Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05243342




Registration number
NCT05243342
Ethics application status
Date submitted
1/02/2022
Date registered
17/02/2022
Date last updated
6/05/2024

Titles & IDs
Public title
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
Scientific title
A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Secondary ID [1] 0 0
GO43073
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma 0 0
Condition category
Condition code
Cancer 0 0 0 0
Other cancer types

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - XmAb24306
Treatment: Drugs - Daratumumab

Experimental: Dose escalation - Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD)

Experimental: Dose expansion - Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D)


Treatment: Drugs: XmAb24306
XmAb24306 will be given via intravenous (IV) infusion

Treatment: Drugs: Daratumumab
Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter)
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of participants with adverse events (AEs)
Timepoint [1] 0 0
Up to approximately 3 years
Secondary outcome [1] 0 0
Serum concentration of XmAb24306
Timepoint [1] 0 0
Baseline to approximately 3 years
Secondary outcome [2] 0 0
Objective response rate (ORR)
Timepoint [2] 0 0
Baseline to approximately 3 years
Secondary outcome [3] 0 0
Prevalence of XmAb24306 anti-drug antibodies (ADAs)
Timepoint [3] 0 0
Baseline to approximately 3 years
Secondary outcome [4] 0 0
Incidence of XmAb24306 ADAs
Timepoint [4] 0 0
Baseline to approximately 3 years

Eligibility
Key inclusion criteria
- Life expectancy of at least 12 weeks

- Measurable disease, as defined by the protocol

- Participants must have received a minimum of 3 prior lines of therapy, including at
least one PI, one IMiD, and an anti-CD38 monoclonal antibody

- Best response of stable disease or better with at least one prior anti-CD38 monoclonal
antibody containing line of treatment
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with
exceptions defined by the protocol

- Prior allogeneic stem cell or solid organ transplantation

- Autologous stem cell transplantation within 100 days prior to initiation of study
treatment

- Significant cardiovascular disease

- Known clinically significant liver disease

- Active or history of autoimmune disease or immune deficiency

- Known active infection requiring IV anti-microbial therapy within 14 days prior to
first study drug administration

- Primary or secondary plasma cell leukemia

- Current CNS involvement by MM

- Other protocol defined inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/04/2022
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/07/2026
Actual
Sample size
Target
60
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
SA,VIC,WA
Recruitment hospital [1] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [2] 0 0
Alfred Hospital - Melbourne
Recruitment hospital [3] 0 0
The Perth Blood Institute - Nedlands
Recruitment postcode(s) [1] 0 0
5000 - Adelaide
Recruitment postcode(s) [2] 0 0
3004 - Melbourne
Recruitment postcode(s) [3] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
Denmark
State/province [1] 0 0
Odense C
Country [2] 0 0
Denmark
State/province [2] 0 0
Vejle
Country [3] 0 0
Norway
State/province [3] 0 0
Oslo
Country [4] 0 0
Spain
State/province [4] 0 0
Barcelona
Country [5] 0 0
Spain
State/province [5] 0 0
Salamanca

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Genentech, Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of
XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable
of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or
refractory (R/R) MM who have received a minimum of three prior treatments, including at least
one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal
antibody.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05243342
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Trials
Address 0 0
Hoffmann-La Roche
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Reference Study ID Number: GO43073 https://forpatients.roche.com/
Address 0 0
Country 0 0
Phone 0 0
888-662-6728
Fax 0 0
Email 0 0
global-roche-genentech-trials@gene.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05243342